• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Quality Control on Coronary Stents Increased Following China’s Recent Centralized Procurement Program

Quality Control on Coronary Stents Increased Following China’s Recent Centralized Procurement Program

Tuesday, 24 November 2020 / Published in Medical Device, News, NMPA Registration in China

Quality Control on Coronary Stents Increased Following China’s Recent Centralized Procurement Program

On November 11, the NMPA (National Medical Products Administration) announced (No.103 – 2020) six principles to strengthen the market surveillance of coronary stents following the recent implementation of a centralized procurement in China.

In summary of the six principles, the NMPA advises the provincial MPAs to ensure the manufacturers:

  • Meet the product standards for quality and safety
  • Strengthen the inspection over the manufacturing process
  • Supervise the circulation of coronary stents
  • Establish a traceability system for product recalls
  • Effectively control post-market risks with adverse events monitoring
  • Reinforce the coordination and communication between internal departments

Highlights from the Centralized Procurement of Coronary Stents

On November 5, the Chinese government held a conference meeting at Tianjin city in China to unveil the results of the centralized procurement of coronary stents.  

  • Ten varieties of coronary stents from eight enterprises won the bidding including Boston Scientific and Medtronic
  • In comparison to 2019, the average price of the coronary stents has decreased by 93% from approx. 13,000 rmb to approx. 700 rmb
    • 92% decrease for the average price of domestic products
    • 95% decrease for the average price of importing products
  • The procurement program saved up to 10.9 billion rmb.
  • All the patients in China will expect to be treated with the procured coronary stents by January 2021.

Important Takeaways for Manufacturers

Coronary stents are mainly used to treat patients with cardiovascular diseases (CVD), which is ranked as the third most fatal disease type in the Chinese population. Becuase some people expressed concerns about the quality of the final product following the centralized procurement implementation, China has released six principles (as mentioned above) to reinforce the quality control of the stent products. In addition, China’s NHSA (National Healthcare Security Administration) has confirmed that the enterprises of all winning bids had successfully passed the national quality tests, and the stents could be traced for post-market surveillance.

The procured coronary stents are expected to be ready in China by January 2021, but available for treatments in public hospitals only. Based on the government measures and plans up until now, private hospitals in China will remain unaffected by the centralized procurement.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Coronary stents, procurement, Quality control

What you can read next

china class I medical device filing
China class I medical device filing clarification
Update of Administrative Measures for the Clinical Use of Medical Devices
Clinical Evaluation Reports can be Created Based on Real-World Data

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP